NVO
Novo Nordisk A/S
NVO offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
SNDA
Sonida Senior Living, Inc.
SNDA has the edge over NVO overall, supported by lower modeled downside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SNDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Weak |
SNDA's revenue is currently strong, but its profitability, cash flow and balance sheet are weak.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SNDA PE Valuation
SNDA has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SNDA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
SNDA has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SNDA on earnings quality, reporting a profit while its opponent remains loss making.
SNDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.36 | -$2.01 |
| Q2 2026 | -$6.20 | -$3.43 |
| Q1 2026 | -$5.84 | -$2.37 |
| Q4 2025 | -$4.22 | -$3.68 |
| Q3 2025 | -$3.35 | -$1.96 |
| Q2 2025 | -$2.77 | +$0.43 |
| Q1 2025 | -$3.47 | +$0.98 |
| Q4 2024 | -$0.54 | +$3.31 |
SNDA is still losing money, but far less than before: $5.36 per share over the past year, against $134.88 at its worst in late 2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SNDA on profitability, with a higher operating margin.
SNDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $210.2M | +114% |
| Q2 2026 | $207.6M | +122% |
| Q1 2026 | $122.6M | +33% |
| Q4 2025 | $97.7M | +6.2% |
| Q3 2025 | $98M | +31% |
| Q2 2025 | $93.5M | +33% |
| Q1 2025 | $91.9M | +36% |
| Q4 2024 | $91.9M | +40% |
SNDA has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -9.3% | +6.5 points |
| Q2 2026 | -2.6% | -0.2 points |
| Q1 2026 | -24% | -46 points |
| Q4 2025 | -22% | -15 points |
| Q3 2025 | -16% | -9.2 points |
| Q2 2025 | -2.4% | -0.4 points |
| Q1 2025 | 22% | +25 points |
| Q4 2024 | -7% | -0.1 points |
SNDA's operating margin was −9.3% last quarter, up 6.5 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over SNDA on cash generation, producing positive trailing cash flow while its opponent burns cash.
SNDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $13.6M | +360% |
| Q2 2026 | -$3.7M | -292% |
| Q1 2026 | -$42.6M | -$38.1M |
| Q4 2025 | -$9.3M | +$1.1M |
| Q3 2025 | $3M | +$8M |
| Q2 2025 | $1.9M | +$3.6M |
| Q1 2025 | -$4.5M | +$5.4M |
| Q4 2024 | -$10.4M | -$6.6M |
SNDA has burned cash in most quarters: −$42M over the past year, against −$10M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SNDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SNDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +821K shares |
| 1 year | +163% | +29.5M shares |
| 3 years | +649% | +41.3M shares |
| 5 years | +2077% | +45.4M shares |
SNDA has 48M diluted shares, up 163% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2022 | $44,000 |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over SNDA on leverage, with a lower net debt burden relative to earnings.
SNDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 32.9x | High |
| Q2 2026 | 72.2x | High |
| Q4 2025 | 18.1x | High |
| Q3 2025 | 13.0x | High |
| Q2 2025 | 11.5x | High |
| Q1 2025 | 11.5x | High |
| Q4 2024 | 21.7x | High |
| Q3 2024 | 20.8x | High |
SNDA's net debt is more than 20 years of its operating earnings (EBITDA), up from 11 years a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SNDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 9.7 | Oversold |
SNDA's weekly RSI is 39 (neutral) and its Stochastic is 10 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SNDA PE vs Healthcare Sector
| Metric | SNDA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SNDA has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
SNDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $35.0 | 5.3% below |
| 20 week MA | $37.9 | 12% below |
| 50 week MA | $35.7 | 7% below |
| 100 week MA | $30.4 | 9.1% above |
| 200 week MA | $23.7 | 40% above |
SNDA has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
SNDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $47.6 | $12.9 | -73% |
| 2021 | $12.9 | $28.6 | +122% |
| 2022 | $28.6 | $11.7 | -59% |
| 2023 | $11.7 | $9.66 | -17% |
| 2024 | $9.66 | $22.9 | +137% |
| 2025 | $22.9 | $32.3 | +41% |
| 2026 YTD | $32.3 | $33.2 | +2.8% |
SNDA has the edge over NVO on returns for 2026, with the stronger performance.